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Abstract
Mesenchymal stem cells (multipotent stromal cells; MSCs) have been under investi-
gation for the treatment of diverse diseases, with many promising outcomes achieved
in animal models and clinical trials. The biological activity of MSC therapies has not
been fully resolved which is critical to rationalizing their use and developing strate-
gies to enhance treatment efficacy. Different paradigms have been constructed to
explain their mechanism of action, including tissue regeneration, trophic/anti-
inflammatory secretion, and immunomodulation. MSCs rarely engraft and differenti-
ate into other cell types after in vivo administration. Furthermore, it is equivocal
whether MSCs function via the secretion of many peptide/protein ligands as their
therapeutic properties are observed across xenogeneic barriers, which is suggestive
of mechanisms involving mediators conserved between species. Oxidative stress is
concomitant with cellular injury, inflammation, and dysregulated metabolism which
are involved in many pathologies. Growing evidence supports that MSCs exert anti-
oxidant properties in a variety of animal models of disease, which may explain their
cytoprotective and anti-inflammatory properties. In this review, evidence of the anti-
oxidant effects of MSCs in in vivo and in vitro models is explored and potential mech-
anisms of these effects are discussed. These include direct scavenging of free
radicals, promoting endogenous antioxidant defenses, immunomodulation via reac-
tive oxygen species suppression, altering mitochondrial bioenergetics, and donating
functional mitochondria to damaged cells. Modulation of the redox environment and
oxidative stress by MSCs can mediate their anti-inflammatory and cytoprotective
properties and may offer an explanation to the diversity in disease models treatable
by MSCs and how these mechanisms may be conserved between species.
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1 | INTRODUCTION
Mesenchymal stem cells (multipotent stromal cells; MSCs) have been
used as tools to treat a broad range of diseases in animal models due
to their unique characteristics such as host immune evasion, rapid
expansion, and their affluence in adult bone marrow and adipose tis-
sue. The positive outcomes of these studies have driven hundreds of
clinical trials into their application for diabetes, inflammatory disorders
and various liver, kidney, lung, cardiovascular, musculoskeletal, neuro-
logical, and gastrointestinal diseases.1 While several trials have dem-
onstrated the therapeutic potential of MSCs, the failure to
incorporate MSCs into current treatment regimens can be, in part,
attributed to the lack of understanding pertaining to their biological
mechanisms of action.
Initially, MSCs were explored as tools of regenerative medicine to
replace damaged tissue.2 However, administered MSCs were rarely
observed to differentiate and effectively engraft into host tissues
despite demonstrating favorable effects in many disease models.3 Fur-
thermore, the secretome of MSCs was identified to be therapeutic in
many disease models in vitro and in vivo. Together, this resulted in a
paradigm shift in recognition of the trophic actions of MSCs.4 Despite
extensive research investigating the anti-inflammatory and trophic
constituents of the MSC-derived secretome, the therapeutic mecha-
nisms of MSCs remain incompletely resolved.5 MSCs demonstrate
therapeutic attributes across xenogeneic barriers and, therefore, the
therapeutic mechanisms of MSCs may be similar between species.
There is strong evidence that the effects of MSCs are mediated via
the secretion of protein/peptide ligands; however, it is equivocal
whether these ligands are effective across xenogeneic barriers.
Recently, the role of MSCs in ameliorating oxidative and
nitrosative injury has received considerable attention. The reduction-
oxidation (redox) environment regulates many physiological and path-
ophysiological mechanisms in cellular biology. Antioxidant effects of
MSC therapy have been observed in various disease models such as
diabetic injuries to the kidney, retina, sensory neurons, brain, and
bone formation; chemotherapy- or radiation-induced injury to the
lungs, gonads, aorta, and brain; ischemic injury of the brain, heart, kid-
ney, and liver; and traumatic injury to the spine and testis, cognitive
disorders, gastrointestinal inflammation, septic injuries, and aging
(Figure 1; Table 1). MSCs can directly reduce oxidative stress-related
injury in vitro in glial cells, neurons, cardiomyocytes, renal cells, endo-
thelial cells, immune cells, hepatocytes, islet cells, fibroblasts, skeletal
muscle, and other cells (Table 2). Oxidative stress is concomitant with
cellular injury, inflammation, and dysregulated metabolism and, there-
fore, is a key pathophysiological mechanism of many diseases. Oxida-
tive stress and redox imbalance are mediated by molecular
constituents that are present in all living cells and share similar func-
tions. Thus, the ability of MSCs to regulate these processes may offer
an explanation to the diversity of disease models treatable by MSCs
and to the effects of MSCs conserved between species.
Oxidative stress refers to a deviation from the physiological redox
state and an increase in pro-oxidants, or free radicals, that structurally
change lipids, proteins, and DNA in a way that causes pathology or
damage to a cell or tissue.6 The most widely studied free radicals are
reactive oxygen species (ROS), which can also include reactive mole-
cules that have a stable charge. The three major endogenous ROS
include the superoxide anion (O2
.−), hydroxyl radical (•OH), and
hydrogen peroxide (H2O2).
7,8 O2
.− is predominantly generated by nic-
otinamide adenine dinucleotide phosphate reduced (NADPH)-oxidase
(NOX) family enzymes or, by the mitochondria, as a by-product of
oxidative phosphorylation.9 The level of mitochondria-derived O2
.−
depends on metabolic substrates, cytosolic Ca2+ levels, pH, and
oxygen tension.10 O2
.− generated from complexes of the electron
transport chain (ETC) are highly reactive and can damage the mito-
chondrion.11 The detoxification of O2
.− into H2O2 is mediated by
superoxide dismutase (SOD).9 However, H2O2 can also be generated
in various metabolic processes and by dual oxidases (DUOX).12 While
H2O2 is more stable than O2
.−, its detoxification is crucial as it pos-
sesses a weak peroxide bond that makes it susceptible to reacting
with metals, such as Fe2+, to generate reactive •OH through the
Fenton reaction.13 Both, H2O2 and O2
.−, are diffusible across cell
membranes and can promote cell death and inflammatory signal-
ing.14,15 Several studies have demonstrated that MSCs can reduce
ROS and biomarkers of oxidative stress. In this review, evidence of
direct and indirect antioxidant mechanisms of MSC therapies is
explored.
2 | MSCs ARE RESISTANT AND RESPOND
TO OXIDATIVE STRESS
The therapeutic properties of MSCs have been explored in many
models of disease associated with high levels of ROS and biomarkers
of oxidative injury. MSCs must survive these volatile environments to
exert their therapeutic effects, which can present as a challenge for
their engraftment after administration. Nonetheless, several studies
Significance statement
The role of mesenchymal stem cells (MSCs) in ameliorating
oxidative and nitrosative injury has received considerable
attention in recent years. The reduction-oxidation (redox)
environment regulates many physiological and pathophysio-
logical mechanisms in cellular biology. Oxidative stress and
redox imbalance are mediated by molecular constituents
that are present in all living cells and share similar functions.
The ability of MSCs to regulate these processes may offer
an explanation to the diversity of disease models treatable
by MSCs and to the effects of MSCs conserved between
species. In this review, evidence of direct and indirect anti-
oxidant mechanisms of MSC therapies is explored.
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have demonstrated that MSCs are highly resistant to oxidative insult.
The oxidative effects of ionizing radiation are limited on MSCs which
have been attributed to their ability to directly scavenge free radi-
cals.16 It has been demonstrated that MSCs are resistant to oxidative
and nitrosative stimuli in vitro which is associated with constitutively
expressed antioxidant enzymes SOD1, SOD2, catalase (CAT), and glu-
tathione peroxidase (GPx), in addition to high levels of the antioxidant
glutathione (GSH).17 Depletion of GSH results in a loss of tolerance to
oxidative stress. MSCs also constitutively express heat-shock protein
70 (HSP70) and sirtuin (SIRT)3,18 which may also play a role in the
resistance of MSCs to oxidative/nitrosative injury. SIRT1 is also
required for MSC survival against H2O2 and its overexpression has a
protective effect.19 Likewise, SIRT6 has been suggested to confer
resistance to oxidative insult and basal ROS production in MSCs via
downstream production of antioxidants including heme oxygenase-1
(HO-1).20 Overexpression of HO-1 ameliorates elevations in ROS and
cellular senescence in SIRT6-null MSCs and, therefore, appears to be
a critical component of the survival mechanism of MSCs in oxidative
environment.20
In addition to wielding constitutive antioxidants, MSCs are
also capable of significant adaptions in response to redox stress.
MSCs exposed to lipopolysaccharide (LPS) produce oxidative and
nitrosative free radicals.18 In parallel, several adaptive processes
are observed including the upregulation and/or nuclear transloca-
tion of redox-sensitive factors (nuclear factor kappa-B [NFκB],
thioredoxin [TRX1], apurinic/apyrimidinic endonuclease redox
effector factor-1 [APE1/Ref-1], nuclear factor erythroid 2-related
factor 2 [NRF2], forkhead box O3 [FOXO3]. and HO-1), as well as
mitochondrial remodeling and autophagy. Similarly, MSCs exposed to
hypoxic conditions (1.5%-2% O2) exhibit increased intracellular ROS
and cells respond by upregulating the expression of hypoxia-
inducible factor 1 alpha (HIF-1α), erythropoietin receptor, CAT,
F IGURE 1 Antioxidant effects of MSC therapies. MSCs exhibit antioxidant properties directly by scavenging of free radicals and donating
mitochondria or indirectly by upregulation antioxidant defenses in other cells and altering cellular bioenergetics. The immunosuppressive
properties of MSCs can also avert the generation of reactive oxygen species (ROS). These mechanisms reduce oxidative stress, which associates
with the therapeutic benefit of MSCs in an array of pathologies
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TABLE 1 Antioxidant activity of MSCs in disease models
Application Model MSCs used Effects of MSC treatment Antioxidant mechanisms References








# Apoptosis in thymus and kidney
" Proliferation in thymus and kidney
" Mature immune cells
" Skeletal muscle growth
# Osteoporosis
" Bmi-1 in liver, kidney, thymus, muscle,
spleen, lung, and bone marrow
# H2O2, "CAT, "SOD in the heart, liver,
spleen, lung, kidney, BM and thymus,
# ROS in all except heart.
# DNA damage in cells of BM, spleen, lung
and thymus






Rat mesenchymal stem cells
(H4320-1)
# Fibrosis # NRF2, # NQO1,
# HO-1, # γ-GCS
# Lipid peroxidation,
" SOD activity




Human BM-MSCs cell line
Ue6E7T-2
# Collagen # DNA oxidation
# ER stress marker BiP
Effects negated by silencing STC-1 and
enhanced by STC-1 over expression
127
Cisplatin-induced
acute kidney injury (rat)
Human UC-MSC exosomes # Blood urea nitrogen (MSC-CM and
fibroblast exosomes had no effect)
# Creatinine (MSC-CM and fibroblast
exosomes had no effect)
# Gross morphological damage
# Apoptosis (TUNEL)
" PCNA










" Cognitive function " Maximal respiratory capacity and spare
respiratory capacity of mitochondria
# Morphologically atypical mitochondria
112







Cisplatin-induced renal injury (mouse) Mouse BM-MSC-CM # Weight loss
# Serum creatinine levels
# c-caspase 3 expression
# Gross morphological damage
• HO-1 −/− MSCs did not demonstrate
therapeutic value
94
Lung radiation injury (mouse) Mouse aorta-derived and
BM-MSCs
# Lung fibrosis • Aorta and BM-MSCs secrete SOD1
" SOD1 expression in irradiated lung
• SOD1 mimetic replicated effect
of MSCs
59







" Total antioxidant capacity
55













Human AT-MSCs " Cognitive function
# Neuron loss
# Caspase 3















Db/Db mouse model of type 2 diabetes Mouse amniotic fluid
MSCs













Rat BM-MSC and exosomes " Cognitive function
Hippocampus (CA1):
• No change in neuronal numbers
• Exosomes colocalized with
astrocytes and can be detected in
microglia and neurons
# Lipid peroxidation 26
Diabetic retinopathy (mouse) Mouse AT-MSCs Intravitreal
injection
# Retinal ganglion cell loss
" NGF, bFGF and GDNF
" TSP1
# ROS and lipid peroxidation 28
STZ-induced diabetic osteoarthritis
(mouse)
Mouse AT-MSCs " Chondrocytes
# RAGE, NFκB
# Lipid peroxidation 128
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TABLE 1 (Continued)
Application Model MSCs used Effects of MSC treatment Antioxidant mechanisms References
STZ-induced sensorial diabetic
Neuropathy (mouse)
Mouse BM-MSCs • Improved pain-like
behaviors








Rat BM-MSCs • Normalization of gene expression
associated with cardiac glucose and
fatty acid uptake (IRS-1, GLUT4,
PPARα, PGC-1, CPT1a and
SREBP-1c)
# c-caspase 3, Bax and " Bcl-2
# Cardiac fibrosis
# Total oxidant content in serum








" Apoptosis in serum-starved MSC# TNFα,
NFkB in lungs and kidney
# Mitochondrial Bax and " Bcl-2 in lungs
and kidney
• “Healthy”MSCs had no effect
# Protein oxidation in kidney
" NQO1 and HO-1 in the lungs
92








Acute lung injury (mouse)
Mouse BM-MSCs # Edema # MPO activity
" CAT, SOD, GPx, glutathione reductase
and GSH




• More favorable results (#morphological lung damage, iNOS expression and lipid




Mouse BM-MSCs " Cys but ND to lung fibroblast
• Redox homeostasis




ND to glutathione disulfide (GSSG) or
cysteine (CySS)
# GSH/GSSG redox potential
# Cys/CySS redox potential, ND to lung
fibroblast
51
Freund's adjuvant-induced arthritis (rat) Rat BM-MSCs # Antinuclear antibodies
# TNFα, IL-9 and IL-4
" IFNγ and TGFβ
# Immune cell infiltration
# Cartilage and bone loss
# Lipid peroxidation
" GSH" SOD activity
66
HOCl-induced systemic sclerosis (mouse) Mouse BM-MSCs Serum:
# Systemic sclerosis biomarker (SCL-70)
Skin and lung:
# Collagen, # αSMA
# TGFβ1
# Advanced oxidation protein products
" Total antioxidant capacity
57
IL-10 −/− model of colitis (mouse) Human BM-MSCs # TNFα, IFNγ, IL-4 and p-NFκB # O2.− and H2O2
# Lipid peroxidation




Human AT-MSCs # Neutrophil accumulation
# Vascular permeability • Effects dependent on
SOD3 expression by MSCs
79
LPS-induced lung injury (rat) Rat BM-MSCs # Lung edema
# Bronchoalveolar lavage protein
# Bronchoalveolar lavage cells
# Neutrophils












Severe acute pancreatitis (rat) Human BM-MSCs # Serum amylase and lipase
# Pancreatic damage
# Inflammatory cells
• MSCs migrated to tissue stimulated:
# Pro-inflammatory cytokines: TNFα,
IL-1β, IL-6
• MSCs migrated to tissue stimulated:
# Lipid peroxidation
" SOD activity, " GPx
# iNOS
67
Severe acute pancreatitis (rat) Rat BM-MSCs # Pancreatitis score
• Inhibition of HO-1
by zinc protoporphyrin




# ROS and lipid peroxidation













Metabolic renovascular disease in swine Swine AT-MSC
extracellular vesicles
" Capillary density • Extracellular vesicles contained
antioxidant proteins:
Glutathione Peroxidase 1,4,6,7, GST
Zeta 1, SOD1-3, Peroxiredoxin 1-6,
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TABLE 1 (Continued)
Application Model MSCs used Effects of MSC treatment Antioxidant mechanisms References








Liver disease Acetaminophen-induced acute liver
failure (mouse)
Human UC-MSCs • MSC pretreatment and
post-treatment of induced liver in
injury
" Survival and liver weight
# Biomarkers of liver failure
# Apoptotic cells and necrotic tissue
# IL-6 only observed with pretreatment
" GSH
" SOD activity
# Lipid peroxidation only observed with
pretreatment
38
CCl4-induced liver fibrosis (mouse) Human BM-MSCs # p47-phox cells # Lipid peroxidation
" SOD activity, CAT and GSH
68
CCl4-induced liver injury (mouse) Allogeneic BM-MSC " Serum albumin
# Serum ALT and AST
# Expression of TNFα, IL-6, type 1 collagen
and αSMA
• MSCs outperformed hematopoietic
stem cells in all assays
# MPO
" SOD and catalase
# Lipid peroxidation
50










# Lipid peroxidation 130
N-diethylnitrosamine-induced
hepatocarcinoma (rat)
Rat BM-MSCs Administration of MSCs at early stage:
# Tumor incidence
# Tumor volume









Canine BM-MSCs # Lung injury
# Fibrosis
" Total antioxidant capacity
# Lipid peroxidation
58
Lung diseases Cigarette smoke-induced chronic
obstructive pulmonary disease (guinea
pig)
Guinea pig AT-MSCs
IV and intratracheal delivery
• No effect on emphysema score " Thiol after IV administration# Lipid peroxidation after IV
and intratracheal delivery
131










APP/PS1 transgenic model of Alzheimer's
disease (mouse)
Rat AT-MSCs " Recognition in behavioral test
" Neurogenesis
# ROS 32
Chronic ethanol intake (rats) Human AT-MSCs • AT-MSCs activated by TNFα and
IFNγ
#ETOH intake
#Relapse after ETOH deprivation
# Hippocampal GSSG/GSH 86
Collagenase induced-intracerebral
hemorrhage (rat)
Rat BM-MSCs # Apoptosis
# Edema
# Blood–brain barrier permeability
# Pro-inflammatory cytokines





Pilocarpine induction of temporal lobe
epilepsy (rat)







Spontaneous stroke (rat) Rat BM-MSCs • " Bcl-2 expression





Tg2576 mice (Alzheimer's disease) Human UC-MSCs • Improved cognitive function
Effects on hippocampus:




" nNOS "total NO
43
YG8 transgenic model of Friedreich's
ataxia (mouse)
Mouse BM-MSCs • Improved performance on behavioral
tests
" BDNF, NT3, and NT4 in dorsal root
ganglia (DRG)
" GFAP, Tuj1, and MAP2 in DRG
" Bcl-2
" Frataxin
# SOD2 and SOD3" CAT and GPx1 81
Oxygen
tension injuries
Acute ischemic stroke (rat) Swine AT-MSCs # Infarct area
# Inflammatory cytokines
# c-caspase 3 # c-PARP
# γ-H2AX
#cytosolic cytochrome c
# NOX1 and NOX2
# Protein oxidation
102
Acute myocardial infarction (swine) Swine BM-MSCs






# NOX1 and NOX2
103
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HO-1, and antiapoptotic Bcl-2 family of proteins.21 Exposure of
MSCs to hypoxia during in vitro culture can enhance their anti-
inflammatory, antioxidative, and cytoprotective properties.21-23 This
suggests that the ability of MSCs to tolerate and respond to oxida-
tive environment may be critical to their engraftment and therapeu-
tic efficacy at sites of tissue injury.
TABLE 1 (Continued)
Application Model MSCs used Effects of MSC treatment Antioxidant mechanisms References





• Silencing of SOD2 in MSCs inhibits
therapeutic effect of extracellular
vesicles
SOD2 mimetic restored effects of MSC
80
I/R model of laparoscopic partial
hepatectomy (swine)






Kidney from acute I/R injury (rat) Rat AT-MSCs (cells and
exosomes)
• MSCs and exosomes improved
kidney function
# Histological injury score
# Pro-inflammatory cytokines
# TGFβ# c-caspase 3, c-PARP,
mitochondrial Bax, cytochrome c
translocation
• Additive effects with MSCs and
exosomes
# NOX1 and NOX2
# Oxidized protein
# MPO
# γ-H2AX DNA damage
104
Kidney ischemia (rat) Human WJ-MSC
Extracellular vesicles
# Renal injury score
# Apoptosis
" Nuclear NRF2






Myocardial I/R injury (mouse) HuES9.E1 derived MSC
exosomes
# Infarct size in vivo and ex vivo
• Ex vivo results suggest direct effect
on myocardium
• Disrupted exosomes did not #
infraction ex vivo
" Contraction and relaxation
# End-diastolic pressure
" pAkt, pGSK3 alpha/beta and
# pJnk
# Peripheral leukocytes




Neonatal hyperoxic lung injury (rat) Human UCB-derived MSCs # Apoptosis
# Pro-inflammatory cytokines







Rat BM-MSC-CM # Pulmonary hypertension
# Right ventricular hypertrophy
# Pulmonary arterial medial wall thickness
# Gross morphological damage to alveoli
" Therapeutic value from the CM of
hyperoxic MCSs compared to normoxic
MSCs
• Lung fibroblast CM had
no therapeutic value
" hydroxyl radical antioxidant capacity in
MSCs compared with lung fibroblast
61
Renal I/R injury (rat) Rat BM-MSCs # Cellular degeneration (histopathology)
" EGF MSCs had no effect on pERK1/2
• MSCs had no effect









• Improved kidney function








" Metabolites TCA cycle-associated
metabolites
# Fructose and sorbitol—glycolysis
associated
" GSH/GSSG and Cys/CySS
ratios
87
Small bowel I/R injury (rat) Rat AT-MSCs # Intestinal permeability
# TNFα and NFκB
# Protein oxidation and lipid peroxidation
# Cytosolic cytochrome c, c-caspase 3,





# MPO and iNOS
# NOX1 and NOX2





Ovarian tissue autograft (mouse) Mouse AT-MSCs " Graft efficacy
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3 | EFFECT OF MSCs ON OXIDATIVE
STRESS BIOMARKERS AND ROS
In disease models, oxidative stress is typically quantified via bio-
markers of oxidation to DNA and proteins or lipid peroxidation.
Administration of MSCs has been demonstrated to reduce levels of
one or more of these markers in a variety of animal models associ-
ated with oxidative stress (Table 1). Injection of MSCs themselves
may not be critical to their antioxidant effects as administration of
their conditioned medium (CM) also reduced lipid peroxidation in a
model of ureteral obstruction-induced kidney injury.24 Administra-
tion of MSC-derived exosomes was also effective to rescue protein
oxidation and lipid peroxidation in animal models of septic and
hyperglycemic brain injury and cognitive impairment.25,26 Likewise,
DNA oxidation and lipid peroxidation caused by cisplatin-induced
kidney damage are alleviated by exosomes from human umbilical
cord-derived MSCs (UC-MSCs); these results were confirmed
in vitro with renal proximal tubular cells.27 Treatments with MSCs
were also demonstrated to reduce levels of ROS in animal models
of diabetic retinopathy and nephropathy, severe acute pancreatitis,
ureteral obstruction-induced kidney damage, Alzheimer's disease,
and metabolic renovascular disease.24,28-32 Specifically, MSC treat-
ments have been shown to reduce levels of H2O2 in intestinal
inflammation and several organs in a model of premature aging.33,34
MSCs also reduced levels of O2
.− in colitis and spontaneous
stroke.34,35
Typically, the reduction of oxidative stress markers by MSC treat-
ments is associated with functional recovery and positive outcomes in
animal models. The exception to this is the diversity of responses at
various stages of hepatocarcinoma whereby antioxidant effects of
MSCs reduce tumor burden at the early stages of disease by
protecting the integrity of DNA but increase tumor progression at the
late stages of the disease possibly by reducing ROS-associated cell
death.36 The timing of treatments may also affect MSCs ability to atten-
uate oxidative stress as pretreatment with MSCs is more effective to
prevent oxidative stress in septic lung injury and acute liver failure.37,38
Several studies have also investigated the therapeutic proper-
ties of MSCs on nitrosative stress which is particularly of interest
in neural diseases. MSCs reduced the volatile peroxynitrite
(ONOO−) in a model of intracerebral hemorrhage and nitrite
levels in diabetic sensory neuropathy.39,40 In a model of radiation-
induced neurological complications, intranasal delivery of MSCs
reduced inducible nitric oxide synthase (iNOS) expression and oxi-
dative stress biomarkers, which are associated with improved cog-
nitive performance and neuronal survival.41 In a model of spinal
cord injury, adipose tissue-derived MSCs (AT-MSCs) also demon-
strated antioxidant activity with a reduction in lipid peroxidation
and protein oxidation; however, no significant effects were
observed for nitrosylation.42 Furthermore, MSCs have been asso-
ciated with increased nitric oxide (NO) in a model of Alzheimer's
disease which may have been driven by preventing the loss of
neuronal nitric oxide synthase (nNOS).43 Alternatively, several
studies observed a reduction in inflammation-induced iNOS and
nNOS expression after MSC treatment.37,44-47 Overall, while the
majority of studies support antioxidative effects of MSCs, their
antinitrosative effects are unclear and likely to be disease and tis-
sue specific. Furthermore, NO can be produced by nonhuman
MSCs which is thought to be critical to their immunomodulatory
function which may also explain these inconsistent effects on
nitrosative stress.42,48
TABLE 1 (Continued)
Application Model MSCs used Effects of MSC treatment Antioxidant mechanisms References
Traumatic
injuries
Spinal cord injury (canine) Canine AT-MSCs " Motor function
# Hemorrhagic area
# Microglia
# TNFα, IL-6 and COX2
# Lipid peroxidation and protein oxidation 42
Testicular torsion injury (rat) Rat AT-MSCs # Apoptosis # Lipid peroxidation 135
Abbreviations: ALT, alanine aminotransferase; APAF-1, apoptotic protease activating factor 1; AST, aspartate aminotransferase; AT-MSC, adipose
tissue-derived MSC; BAX, Bcl-2-associated X protein; Bcl-2, B-cell lymphoma 2; BDNF, brain-derived neurotrophic factor; bFGF, basic fibroblast growth
factor; BM-MSCs, bone marrow-derived MSC; CAT, catalase; c-caspase 3, cleaved-caspase 3; CM, conditioned medium; CO, carbon monoxide; COX2,
cyclooxygenase-2; c-PARP, cleaved poly (ADP-ribose) polymerase; Cys, cysteine; DRG, dorsal root ganglion; DSS, dextran sulfate sodium; EGF, epidermal
growth factor; ER stress, endoplasmic reticulum stress; GABA, gamma-aminobutyric acid; GDNF, glial cell-derived neurotrophic factor; GFAP, glial fibrillary
acidic protein; GLUT1, glucose transporter 1; GPx, glutathione peroxidase; GSH, glutathione; H2O2, hydrogen peroxide; HO-1, heme oxygenase-1; I/R,
Ischemia / reperfusion; ICAM, Intercellular adhesion molecule; IFNγ, interferon gamma; IL, interleukin; iNOS, inducible nitric oxide synthase; IV, intrave-
nous; LPS, lipopolysaccharide; MAP2, microtubule associated protein-2; MPO, myeloperoxidase; NAD(P)H, nicotinamide adenine dinucleotide phosphate
hydrogen; ND, No difference; NFκB, Nuclear factor κB; NGF, Nerve growth factor; nNOS, neuronal nitric oxide synthase; NO, nitric oxide; NOX, NAD(P)H
oxidase; NQO1, NAD(P)H quinone dehydrogenase 1; NRF2, nuclear factor erythroid 2-related factor 2; NT3 and 4, neurotrophin 3 and 4; O2−, superoxide;
ONOO−, peroxynitrite; p38MAPK, p38 mitogen-activated protein kinases; pAkt, phosphorylated protein kinase B; PCNA, proliferating cell nuclear antigen;
pGSK3, phosphorylated glycogen synthase kinase 3 beta; pJnk, phosphorylated c-Jun N-terminal kinases; pERK1/2, phosphorylated extracellular
signal-regulated kinases 1/2; RAGE, receptor for advanced glycation end products; ROS, reactive oxygen species; SOD, superoxide dismutase; STC-1,
stanniocalcin-1; STZ, streptozocin; TCA cycle, tricarboxylic acid cycle; TGFβ, transforming growth factor beta; TNFα, tumor necrosis factor alpha; TSG6,
TNFα-stimulated gene-6; TSP1, thrombospondin 1; Tuj1, neuron-specific class III beta-tubulin; UC-MSC, umbilical cord-derived MSC; αSMA, alpha-smooth
muscle actin; γ-GCS, gamma-glutamylcysteine synthetase; γ-H2AX, gamma-H2A histone family member X; Δψm, mitochondrial membrane potential; CySS,
cystine (disulfide form of cysteine); GSSG, glutathione disulfide.
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Although studies in cells and animal models unequivocally dem-
onstrate that MSC treatments reduce levels of oxidative stress, albeit
limited data exist from human studies. Nonetheless, favorable out-
comes in a case study utilizing MSCs to treat the lungs of a subject
previously exposed to sulfur mustard gas were attributed to the anti-
oxidant properties of MSCs as evidenced by reduced lipid peroxida-
tion levels in the sputum.49
The antioxidant effects of MSC treatments are likely to be a spe-
cific property of these cells as they are more efficacious than hemato-
poietic stem cells and fibroblast at reducing oxidative stress in carbon
tetrachloride-induced-liver injury and sepsis, respectively.50,51 Like-
wise, fibroblast exosomes have no effect on kidney injury-induced by
ischemia and chemotherapy.27,52
The alleviation of oxidative stress in animal models is associated
with decreased pro-inflammatory cytokines and markers of cellular
death highlighting the close association between these processes. The
precise mechanisms of in vivo MSC treatments are difficult to deter-
mine as cell death, inflammation, and oxidative stress occur concomi-
tantly and perpetuate each other. However, a growing body of
evidence suggests that MSCs have a direct role on suppressing oxida-
tive stress and ROS production which may mediate their antiapoptotic
and anti-inflammatory effects.
4 | ANTIOXIDATIVE MECHANISMS
OF MSCs
The potential for MSCs to attenuate oxidative injury is unequivo-
cally demonstrated by the reduction in ROS and biomarkers of oxi-
dative stress in many disease models. Evidence form in vitro
models suggests that MSCs directly protect cells from oxidative
stimuli (Table 2). This is often associated with a reduction in ROS
suggesting that MSCs avert the negative effects of oxidative stress
by reducing the oxidative stimuli. The antioxidative effects of
MSCs often occur in a paracrine manner in vitro and the adminis-
tration of MSC-conditioned medium (CM) can also reduce oxida-
tive stress in vivo suggesting a paracrine component to their
mechanism.24 Nevertheless, others report that the antioxidant
effects of MSCs can be cell contact dependent53; albeit, these
mechanisms could be disease and tissue dependent. Currently,
MSCs have been proposed to reduce oxidative injury via scaveng-
ing free radicals, enhancing host antioxidant defenses, modulating
the inflammatory response, augmenting cellular respiration and
mitochondrial functions, or donating their mitochondria to protect
damaged cells (Figure 1).37,50,51,53,54
4.1 | Antioxidant defense and scavenging
To maintain redox homeostasis and prevent excessive production of
free radicals, cells rely on a complement of enzymatic antioxidants,
including SODs, CAT, GPx, and small nonenzymatic antioxidants, such
as GSH. After MSC treatments, the total antioxidant capacity of
tissues are enhanced as observed in models of chemotherapy-induced
neuropathy, hyperglycemia-induced cardiac damage, systemic sclero-
sis, hepatocarcinoma, and acute liver injury.36,55-58 MSCs are recep-
tive to oxidative stimuli and exhibit all necessary machinery to
efficiently process ROS.18,59 Furthermore, media conditioned by
MSCs have potent antioxidant capacity indicating that MSCs actively
secrete antioxidants.60 MSC-CM has more effective antioxidant prop-
erties than CM from lung fibroblasts.61 In several models of disease,
MSC treatments upregulate the expression of antioxidant defense
enzymes in vivo (Table 1). Therefore, the antioxidant effects of MSCs
may be explained by their ability to directly scavenge free radicals and
by enhancing antioxidant defenses in host tissues through
upregulation of antioxidant enzymes.
Volatile O2
− is produced during cellular respiration by the mito-
chondria and NOX enzymes during tissue inflammation; O2
− is elimi-
nated by SOD which catalyzes its conversion to H2O2. Antioxidant
effects of MSC treatments have been associated with enhanced SOD
activity or the expression of SODs in models of aging, age-related
erectile dysfunction, chemotherapy-induced pulmonary fibrosis or
gonadotoxicity colitis, pancreatitis, septic lung injury, arthritis, hepato-
toxicity and hepatic ischemia reperfusion injury, Alzheimer's disease,
and ovarian autografts.33,34,37,38,43,50,62-70 MSCs secrete all isoforms
of SOD including SOD1 and SOD2, which are archetypically not
released extracellularly.33,59,71,72 Thus, it is difficult to interpret
whether enhanced SOD activity and/or SOD expression is due to
MSCs or host-tissue-derived SOD. In in vitro studies, MSC-CM or
MSCs in transwell cocultures promote SOD activity in tert-Butyl
hydroperoxide or UV-exposed fibroblasts, H2O2-treated neural stem
cells or retinal ganglion cells, and dexamethasone-induced muscle
atrophy model.60,73-76 These studies suggest that MSCs enhance SOD
activity in cells exposed to oxidative stimuli. Likewise, MSC-CM
increases SOD1 expression in islet cells exposed to pro-inflammatory
cytokines and SOD2 in tert-Butyl hydroperoxide-treated umbilical
endothelial cells.77,78 In endothelial cells, increased SOD2 expression
was regulated by signal transducer and activator of transcription
(STAT3) signaling and knockdown of either SOD2 or STAT3
decreased the antiapoptotic effects of the MSC-CM.77 These find-
ings suggest that MSC upregulation of SOD in host tissues may be
critical to their antioxidant effects. Alternatively, MSCs stimulated
with TNF-α and IFN-γ were found to secrete high levels of SOD3,
which was a major contributor to the antioxidant properties of
MSCs in the amelioration of NO-induced neuronal death in vitro.71
Likewise, SOD3 expression in MSCs was necessary to suppress neu-
trophil respiratory burst and the accumulation in immune complex-
mediated dermal vasculitis.79 Similarly, silencing of SOD2 in MSCs
inhibits the antioxidant properties and therapeutic efficacy of their
exosomes in hepatic I/R injury in vivo and H2O2-treated human fetal
hepatocytes which can be recovered by the addition of a SOD2
mimetic.80
CAT and GPx are responsible for detoxifying H2O2 by its conver-
sion to oxygen and water. MSCs secrete CAT and upregulation of
CAT expression is associated with the therapeutic properties of MSCS
in models of Friedreich's ataxia, radiation-induced aortic injury, septic
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lung injury, and hepatoxicity.33,37,50,68,81,82 Likewise, upregulation of
CAT associates with the antioxidant properties of MSCs in aging and
colitis which parallels measurable reductions in H2O2.
33,34 Exosomes
derived from MSCs also express functional CAT.31,83 Inhibition of
CAT suppresses their protective effects on amyloid-β oligomer-
induced damage to hippocampal neurons indicating that this enzyme
may also mediate antioxidant effects of MSCs.83 MSC treatments
have also been demonstrated to upregulate the expression of GPx in
septic lung injury, severe acute pancreatitis, small bowel ischemia/
reperfusion (I/R) injury, and Friedreich's ataxia.37,67,81,84 MSC-CM can
also enhance GPx activity in fibroblasts under oxidative stimuli.60
Therefore, both CAT and GPx may play a role in MSC treatments in
reducing oxidative stress by the elimination of H2O2 which was com-
monly used as a cell death inducing oxidative stimulus in in vitro
studies.
The glutathione system is critical to scavenging ROS in animals,
plants and fungi. GSH exerts its antioxidant effects by reducing free
radicals and peroxides. During this process, glutathione disulfide
(GSSG) is generated which is converted back to GSH by NADPH and
is catalyzed by glutathione reductase. Increased levels of GSSG to
GSH are suggestive of an oxidative redox state. Conversely, higher
GSH-to-GSSG ratio is observed after MSC treatment in models of
type 2 diabetes, in the hippocampus after chronic ethanol intake and
hypoxia-induced hypertension.85-87 Likewise, MSCs improve GSH-to-
GSSG ratio in sepsis which is not achieved by fibroblast.51 Similarly,
MSCs were found to increase GSH levels in diabetic models, septic
lung injury, arthritis, hepatotoxicity, and epilepsy.37,38,66,68,88-90 These
effects were also observed by MSC-CM in a model of unilateral ure-
teral obstruction which may suggest GSH was host-tissue-derived.24
The effects of MSCs on GSH levels may be mediated by their ability
to upregulate glutathione reductase which was observed in septic
lung injury, acute pancreatitis, and I/R injury of the small bowel.37,67,84
Notably, MSCs have also been shown to upregulate the expression of
glutathione S-transferases (GSTs) in cells and tissues which detoxify
many damaging molecules that arise from redox imbalance such as
peroxidized lipids.88,91 Glutathione reductase and GSTs are secreted
by MSCs via exosomes.31 While GSH has been the best studied scav-
enger in MSC treatments, they have also been demonstrated to
upregulate the expression of the enzyme NAD(P)H quinone oxidore-
ductase 1 (NQO1) which detoxify quinones that contribute to the
generation of ROS in septic lung injury, small bowel I/R injury in vivo,
and cytokine-exposed islet cell in vitro.78,84,92
The multifunctional antioxidant HO-1 has also been implicated in
the therapeutic effects of MSC treatments. HO-1's antioxidant and
therapeutic mechanisms have been attributed to its ability to degrade
heme, which is pro-oxidative and the scavenging abilities of its prod-
ucts, biliverdin and bilirubin. HO-1 expression is inducible in response
to oxidative stress via nuclear factor erythroid 2-related factor
2 (NRF2) which appears to be important in the adaptive responses of
MSCs to inflammation and ROS.18 Downregulation of NRF2 and
HO-1 has been observed after MSC treatment of chemotherapy-
induced pulmonary fibrosis and diabetic sensory neuropathy which
may be explained by a reduction in oxidative stimuli.40,63 Conversely,
the antioxidant effects of MSCs in several other models associate
with upregulation of HO-1 such as radiation-induced aortic injury,
septic lung injury, pancreatitis, and renal injuries caused by altered
oxygen tensions and cisplatin.30,82,92-94 HO-1 was determined to par-
tially contribute to the effects of MSCs in pancreatitis as its inhibition
with zinc protoporphyrin negated some of the effects of MSC treat-
ments, including upregulation of CAT and increased SOD activity,
which may indicate that these processes are downstream of HO-1
activity.30 After MSC treatment of small bowel I/R injury, a larger
number of HO-1 expressing cells were observed which did not appear
to completely colocalize with engrafted MSCs suggesting that treat-
ments may increase HO-1 expression in cells of the host.84 It has been
demonstrated that overexpression of HO-1 in MSCs enhances their
therapeutic activity in septic lung injury which was attributed to its
pro-survival properties.95 Others have reported that MSCs still
respond efficiently to oxidative insult with silenced HO-1 by
upregulating GSH pathway enzymes.96 Nevertheless, the CM of
MSCs derived from HO-1−/− mice are unable to attenuate cisplatin-
induced renal injury and therefore HO-1 appears to have an important
role in the antioxidant properties of the MSC secretome.94
Together, these studies demonstrate that antioxidants secreted
by MSCs and their ability to upregulate host antioxidant defenses
contribute to the suppression of oxidative stress. The exosomes
derived from MSCs appear to be particularly rich in machinery to pro-
cess ROS and can include, but not limited to, GPx, GSTs, SOD1-3, per-
oxiredoxin 1-6, CAT, cytoglobin, prostaglandin-endoperoxide
synthase 1, peroxidasin, albumin, apolipoprotein E, glutathione-
disulfide reductase, and thioredoxin reductase 1-2.31,80 Notwithstand-
ing, recombinant application of factors secreted by MSCs, such as
hepatocyte growth factor (HGF) and basic fibroblast growth factors
(bFGF), has been demonstrated to upregulate Gpx1, CAT, and SOD
activity via SIRT1 and FOXO1 during age-related loss of ovarian func-
tion.97 Mechanisms of antioxidant defense mediated by scavenging of
ROS by MSCs and the host could occur independently or simulta-
neously and are likely to be disease-specific.
4.2 | Antioxidant effects on inflammation
Immune function is regulated by free radicals and the redox system;
leukocytes and pro-inflammatory mediators enhance the formation of
free radicals and perturb the redox environment creating a positive
feedback cycle.98 The immunomodulatory action of MSCs is a well-
documented phenomenon; however, their role in the interactions
between the immune system and oxidative stress is not fully under-
stood. Oxidative and/or nitrosative free radicals unequivocally play a
role in all grades of acute and chronic inflammation. At physiological
levels, they act as cellular signals modifying function and initiating
necessary cell death programs. However, excessive generation of free
radicals and/or inadequate scavenging results in protein oxidation,
lipid peroxidation, and DNA damage that can be detrimental both
intrinsically to the cell and the surrounding microenvironment. The
ROS and reactive nitrogen species involved can take many forms and
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be generated from a variety of sources. Large amounts of the highly
reactive O2
− anion are generated from NOX expressed by innate leu-
kocytes.99 SOD catalyzes the conversion of O2
− to H2O2 which
phagocytes and neutrophils use to generate hypochlorous acid (HOCl)
via myeloperoxidase (MPO).99 Collectively, this is referred to as respi-
ratory burst, a crucial element of the bactericidal response and inflam-
matory signaling. Nonetheless, MPO activity and O2
− are also
associated with various inflammatory diseases. In inflammatory bouts,
there is often a parallel increase in the expression of iNOS in leuko-
cytes and, thus, subsequent generation of the free radical
NO. Nonimmune cells such as epithelial cells are also capable of
expressing iNOS and NOX to generate NO and O2
−.
MSC treatments reduce inflammation and oxidative stress in coli-
tis, pancreatitis, arthritis, sepsis, vasculitis, stroke, myocardial infarc-
tion, hyperoxic lung injury, and I/R injury of the kidneys and bowel
(Table 1). These effects have included a reduction in inflammatory
cytokines TNFα, IFNγ, interleukin (IL)-1β, IL-6, IL-9, and IL-4;
decreased expression of ROS producing enzymes NOX, MPO, and
iNOS; as well as a net reduction in the infiltration of immune cells
such as neutrophils (Table 1). The anti-inflammatory effects of MSCs
in pancreatitis were partially dependent on their expression of the
antioxidant pathway enzyme HO-1.30 Previously, it was demonstrated
in a model of sepsis that MSC treatments can reduce pro-
inflammatory cytokines in the serum and normalize thiol/disulfide
redox pairings responsible for free radical scavenging.51 Decreased
levels of IL-1β and TNFα superseded restoration of redox homeosta-
sis. This suggests that the aversion of oxidative injury was secondary
to the immunomodulation of pro-inflammatory signaling, at least in
acute septic inflammation. Conversely, MSCs can directly reduce oxi-
dative injury in many cell types in vitro; thus, it is likely that MSCs
may also reduce oxidative stress in tissues by mechanism other than
suppressing the immune system.27,54,60,75,77,100 This is highlighted in
in vivo and organotypic ex vivo models of myocardial I/R injury where
MSC-derived exosomes ameliorated infarction injury without altering
leukocyte recruitment.101 In in vivo experiments, protein oxidation
was reduced by MSC-derived exosomes after 1 hour; neutrophils
were yet to infiltrate into the tissue. After 24 hours, MSCs reduced
peripheral blood leukocyte numbers and neutrophil infiltration into
the myocardium; thus, the antioxidative activity of MSCs preceded
signals recruiting leukocytes.101 This suggests that MSCs can attenu-
ate oxidative stress-induced tissue injury first, which can limit the
recruitment of immune cells and subsequent inflammation in this
model. This may be mediated by their ability to suppress NOX1 and
2 on resident cells which are downregulated by MSC treatments in
acute myocardial infarction, sepsis-induced brain injury, acute ische-
mic stroke, I/R injury to kidneys, and small bowel which were all asso-
ciated with reduced inflammation.25,84,102-104
Neutrophils appear to be key mediators of oxidative stress in
inflammation. These cells harbor an abundance of MPO, a major cata-
lyst for hypochlorite and NO-derived oxidants.105,106 MSCs attenuate
the infiltration of neutrophils and reduce MPO levels in several dis-
ease models.50,107,108 MSCs can also directly dampen the respiratory
burst in neutrophils and suppress MPO activity required to produce
free radical required for their pro-inflammatory function which was
dependent on SOD3 and occurs in a paracrine manner.79,80,109 Like-
wise, MSCs can also directly decrease ROS and MPO in stimulated
monocytes and macrophages which suppress their pro-inflammatory
phenotype.110,111 These data suggest that MSCs not only suppress
the immune system to prevent oxidative injury, but also that their
mechanism of immunosuppression is reliant on their antioxidant
properties.
4.3 | Cellular bioenergetics
Free radicals are produced by several metabolic processes and the
mitochondria during cellular respiration. Dysfunction in mitochondria
can cause cellular injury which is mediated through the generation of
O2
.− and proteins that initiate cellular apoptosis. Depolarization of the
mitochondrial membrane potential (Δψm) is a hallmark of mitochon-
drial dysfunction leading to cell death. Hyperglycemia can also cause
oxidative stress via several mechanisms including the formation of
free radical as by-products of glucose auto-oxidation that deplete
antioxidant defense and advanced glycation end products that induce
cellular stress. In models of hyperglycemia, MSC treatments can
reduce the expression of glucose and fatty acid transports in kidney
and cardiac tissue cells, which prevents glucose transport and ROS
generation.29,56 Therefore, the antioxidant effects of MSC treatments
in models of diabetes may be downstream of glycemic control. Con-
versely, regulation of mitochondrial function and oxidative phosphor-
ylation by MSCs has been implicated in several disease models. MSC
treatments improve chemotherapy-induced cognitive impairment,
which associates with enhanced respiratory capacity of the mitochon-
dria.112 The effects of MSCs on the mitochondria appear to occur in a
paracrine manner as MSC-CM increases the oxygen consumption rate
of hypoxia-exposed neonatal porcine islet cells and LPS-treated mac-
rophages.113,114 Similarly, MSC-derived extracellular vesicles suppress
mitochondrial O2
.− levels in H2O2-treated human fetal hepatocytes,
which is associated with a reduction in apoptosis.80
The potential for MSCs to directly attenuate mitochondrial dys-
function has been demonstrated in an in vitro model of I/R injury in
mouse ventricular myocytes.54 Within 5 minutes of reperfusion, cells
exhibited an exaggerated Δψm hyperpolarization, which was reduced
by conditioning the reperfusion solution with MSCs. The exaggerated
hyperpolarization was followed by a continuous depolarization in con-
trols after 15 minutes which was also attenuated by the paracrine
secretion of MSCs. Decay of the Δψm was likely a result of the mito-
chondrial permeability transition pore opening. The exaggerated
hyperpolarization of the Δψm was also averted by a mitochondrial
ROS scavenger which simultaneously decreased mitochondrial O2
−
generation demonstrating the close relationship between these
events. Similarly, MSC secretion decreased mitochondrial O2
−, which
led to the suggestion that MSCs may also attenuate Δψm dysfunction
via scavenging of O2
−.
Depolarization of the Δψm in cisplatin-treated renal proximal
tubular cells has also been reportedly attenuated using exosomes
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derived from UC-MSCs.27 In vitro, BM-MSCs were demonstrated to
upregulate uncoupling protein 2 (UCP2) transcription in H2O2-treated
alveolar basal epithelial adenocarcinoma cells which reduces the for-
mation of mitochondria-derived O2
− by lowering the proton-motive
force across the mitochondrial membrane and provides another
potential mechanism for the alleviation of mitochondrial dysfunc-
tion.100 This was regulated by the paracrine secretion of
stanniocalcin-1 by MSCs, which enhanced UCP2, correlating with cell
survival and decreased ROS generation. MSCs secreted
stanniocalcin-1 may also attenuate inflammation as it decreases mito-
chondrial ROS and subsequent activation of the nucleotide-binding
oligomerization domain (NOD)-like receptor protein 3 (NLRP3)
inflammasome.111 BM-MSCs inhibited the activity of the NLRP3
inflammasome in primed macrophages which is responsible for recog-
nizing damage-associated molecular patterns and initiating the inflam-
matory cascade through activation and secretion of IL-1β.115,116
MSCs have also been demonstrated to secrete the redox-sensitive
protein DJ-1, which has established roles in maintaining mitochondrial
biogenesis and respiratory chain efficiency and could potentially medi-
ate the neuroprotective effects of the MSC secretome as shown in
Parkinson's disease models.117 Collectively, these studies demonstrate
that MSCs can ameliorate mitochondrial dysfunction in a paracrine
manner with diverse therapeutic outcomes.
4.4 | Mitochondrial donation
Recently, a concept has emerged that MSCs may be able to alter oxi-
dative phosphorylation and ROS generation in cells through donation
of mitochondria themselves. Islam et al118 observed mitochondrial
transfer from human BM-MSCs to alveolar epithelium in a mouse
model of LPS-induced lung injury. BM-MSC administration attenuated
decreased intracellular ATP in the alveoli caused by lung injury; nota-
bly, ATP (visualized by a molecular probe) was predominantly restored
at the site of mitochondrial transfer and immediately surrounding
alveoli. MSCs with a mutation in connexin 43, a protein involved in
the formation of gap junctions, were unable to transfer mitochondria
despite being functionally competent and subsequently did not
restore ATP, surfactant secretion, or reduce leukocyte infiltration. This
phenomenon only occurred in LPS-exposed lungs indicating that mito-
chondrial transfer is dependent on stimulants from damaged tissues.
MSCs cultured in hyperoxic (21% O2: normoxic atmosphere) con-
ditions produce high levels of mitochondrial O2
.−, depolarize Δψm,
and induce mitophagy.119 Mitochondria are loaded into phagosomes
and shuttled to the plasma membrane.119 These effects were reduced
by culturing MSCs closer to a normoxic oxygen concentration (5% O2:
hypoxic atmosphere). Macrophages have been observed to phagocy-
tose these vesicles containing the partially depolarized mitochondria,
which can fuse with endogenous mitochondria in macrophages. This
protects silica-exposed macrophages by increasing their oxygen con-
sumption rate and decreasing mitochondrial O2
.− production. These
effects could not be elicited when MSCs were substituted by human
fibroblasts.119 This suggests that mitochondrial transfer may be
stimulated by oxidative stress in MSCs. Conversely, MSCs have also
been demonstrated to engulf mitochondria from other somatic cells
exposed to H2O2. MSCs degraded the engulfed mitochondria which
stimulated HO-1 expression, mitochondrial biogenesis in MSCs, and
the transfer of functional MSCs to damaged cells.53 Inhibition of
mitophagy negated the cytoprotective effects of MSCs in other
somatic cells, which suggests that MSC sensing of damaged mito-
chondria may mediate their therapeutic responses.53 Supporting this,
the cell contact-dependent transfer of mitochondria from
chemotherapy-treated T lymphocytes to MSCs was also determined
to be critical to their ability to decrease mitochondrial O2
.− production
and cell death in T lymphocytes.120 Nonetheless, in this study, mito-
chondrial transfer appeared to be predominately unidirectional and
very few MSC-derived mitochondria were observed in T cells. This
suggests that MSC sensing of mitochondria can promote therapeutic
mechanisms other than mitochondrial donation.120
Although extracellular vesicles can contain whole mitochondria,
several studies suggest that the donation of mitochondria may be
contact-dependent. MSCs have been found to transfer mitochondria
via tunneling nanotubes (TNT) to glucose-deprived and hypoxia-
reoxygenated cardiomyocytes which prevented Δψm depolarization
and cell apoptosis. Albeit inhibition of TNT formation only partially
reversed the effects of MSCs indicating other cytoprotective mecha-
nisms were still active.121 Similarly, MSCs transfer mitochondria to
chemotherapy-treated endothelial cells, which appears to occur in a
unidirectional manner, unlike in T lymphocytes.120,122 Miro1 is impor-
tant to TNT formation and its overexpression in MSCs can enhance
mitochondrial transfer.123 The effects of MSC mitochondrial donation
are sufficient to rescue cellular respiration, proliferation, and motility
in mitochondria-depleted osteosarcoma cells.124 These effects can be
maintained for 45 passages, which highlights the therapeutic potential
of MSC-derived mitochondria.124 Exogenous application of mitochon-
dria isolated from MSCs may also offer therapeutic benefit and are
able to protect dexamethasone-treated muscle cells form oxidative
stress in vitro.125 Albeit, delivery of MSC-derived mitochondria in
in vivo poses a challenge. While several studies have demonstrated
contact-dependent transfer of mitochondria between MSCs and other
cells, MSCs have also been reported to donate mitochondria to LPS-
treated macrophages via secreted extracellular vesicles.114 Exposure
of macrophages to MSC-derived exosomes promoted their indication
to the type 2 phenotype, which exerted anti-inflammatory effects
after adoptive transfer in septic lung injury.114 The effects of MSCs
were dependent on enhancing mitochondrial function in macrophages
and were inhibited by damaging mitochondria in MSCs and blocking
extracellular vesicles.114 The therapeutic use of MSCs to deliver func-
tional mitochondria to damaged tissue is an intriguing concept and
warrants further study; however, another recent advancement
reported by Panfoli et al126 suggests that the exosomes of MSCs are
capable of oxidative phosphorylation independent of the mitochon-
dria. Subsets of MSC-derived exosomes isolated from the umbilical
cord of term newborns were discovered to contain complexes of the
ETC embedded in the membrane. These exosomes possessed an elec-
trochemical membrane potential, consumed O2, and produced ATP.
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The therapeutic application of these exosomes is yet to be investi-
gated; nonetheless, this may present a viable tool to restore
dysfunctional oxidative phosphorylation and ATP synthesis in dam-
aged cells.
5 | CONCLUSION
The presented studies evidently demonstrate that MSCs exhibit anti-
oxidant potential either directly via scavenging of ROS and donating
mitochondria or indirectly by upregulation antioxidant defenses in
other cells and altering cellular bioenergetics. These effects can occur
in combination with the previously recognized trophic and vesicular
components of the MSC secretome acting directly on regenerative
pathways. Likewise, antioxidant and trophic pathways appear to medi-
ate the cytoprotective effect of MSC treatments which are ROS
dependent. MSCs have frequently been utilized in inflammatory dis-
eases to modulate the immune response. In this context, immunosup-
pression can avert ROS generation which is generated by MPO and
NOX enzymes as a part of the inflammatory response. However,
MSCs have now been shown to exert immunosuppressive effects by
dampening ROS production and enhancing mitochondrial function in
macrophages and neutrophils. Therefore, the antioxidant properties
confer a role in the trophic and anti-inflammatory mechanisms of
MSC therapy. Considering that oxidative stress is implicated in almost
every disease, these antioxidant properties, along with regenerative
capacity of MSC seretome, may explain why MSC treatments are use-
ful for such a spectrum of seemingly unlinked pathologies (Figure 1).
Future studies should seek to clarify disease-specific nuances of the
antioxidative mechanisms of MSCs and MSC-derived products. Like-
wise, improving the antioxidant effects of MSCs by enhancing the
expression of antioxidant enzymes or promoting mitochondrial dona-
tion may be useful to optimize MSC-based therapies and improve
outcomes.
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